Jacques Theurillat
Partner, Crossover fund @ Sofinnova Partners
Paris, France
Jacques Theurillat is a startup investor at Sofinnova Partners in Paris. Jacques joined Sofinnova in 2017 and brings the Crossover Team his extensive experience in biopharmaceutical company operations, as well as in making private as well as public investments. His experience in building from the base a team of international investors to deploy a new strategy is also important for the Crossover Team. He is expected totake positions on board of some of the public companies in which the Fund will invest. Jacques Theurillat co-founded in 2008 and managed Ares Life Sciences, a privately owned investment fund with the objective to build and manage a portfolio of companies in life sciences. Jacques built a new team of 9 professionals and invested €1.25bn in six public and private companies including Euromedic International BV, Esaote Spa, Bronchus Technologies Inc, Santhera Pharmaceuricals, Stallergenes SA, Greer Inc. In June 2015, Stallergenes and Greer merged creating the worldwide market leader in Allergy Immunotherapy. Jacques had previously spent almost 20 years in the Serono pharmaceutical group where he was Deputy CEO and Senior Executive Vice President, Strategic Corporate Development, responsible for Serono’s global strategy and in-licensing initiatives. Jacques also served as Serono’s President of European and International Sales & Marketing and CFO. In his various roles at Serono, Jacques was responsible for several major equity financings of the company including the $2bn listing on the NYSE in 2000, one of the largest ever Biotech secondary offering worldwide. Jacques was also involved in the process that led to the sale of the company to Merck KGA for CHF14bn. Jacques is a Swiss barrister and holds Bachelor of Law degrees from both Madrid University and Geneva University. He also holds a Swiss Federal Diploma (Tax Expert) and has a Master’s degree in Finance.
Last updated:
For AI agents: llms.txt
About Sofinnova Partners
Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage.The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential topositively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs.It was headquartered in Paris, Ile-de-France in 1972.
Sofinnova Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alain Tingaud
Venture Partner
|
|||
Cedric Moreau
Partner
|
|||
Dominique Verdier
Operations
|
|||
Edward Kliphuis
Partner
|
|||
|
Jacques Theurillat
Partner, Crossover fund
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
